p16INK4a as a proliferation marker unrelated to HPV expression in odontogenic cysts and tumors.
HPV in situ hybridization
odontogenic cysts
odontogenic rests
odontogenic tumors
p16INK4a expression
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
21
08
2019
revised:
24
10
2019
accepted:
27
10
2019
pubmed:
5
11
2019
medline:
31
1
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
p16INK4a is a tumor suppressor protein that retards cell cycle progression from G1 to S phase. Prior studies have evaluated p16INK4a expression in odontogenic keratocyst and ameloblastoma, but data regarding other odontogenic cysts and tumors have been sparse. With IRB approval, cases from the following entities were identified from archives of the UF Oral Pathology Biopsy Service (2005-2015): benign incidental odontogenic rest, dentigerous cyst, lateral periodontal cyst, calcifying odontogenic cyst, glandular odontogenic cyst, odontogenic keratocyst, orthokeratinized odontogenic cyst, adenomatoid odontogenic tumor, calcifying epithelial odontogenic tumor, and ameloblastoma. All cases were submitted for p16INK4a immunohistochemical testing. Results were scored as follows: nuclear and cytoplasmic staining of <5% cells (score 0), 5%-25% (score 1), 25%-50% (score 2), >50% (score 3). No significant difference in p16INK4a staining was noted between odontogenic cysts and the listed odontogenic tumors (chi-square, P = .540). When comparing lesions with higher recurrence rates (over 25% as reported in the literature) versus lesions with low recurrence rates (under 25%), higher recurrence correlated to significantly higher p16INK4a positivity (chi-square, P = .001). Follow-up testing was performed on 18 cases with "2" or "3" p16INK4a expression scores for high-risk HPV strains through HPV in situ hybridization (ISH) messenger RNA testing with no cases exhibiting a positive result. This study exhibits an association between increased p16INK4a positivity and odontogenic lesions with higher recurrence rates and highlights the role of p16INK4a as a progression marker unrelated to HPV expression in this group of pathologic entities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-81Subventions
Organisme : Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry
Organisme : Clinical Research Committee, Department of Pathology, University of Florida College of Medicine
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Artese L, Piattelli A, Rubini C, et al. P16 expression in odontogenic tumors. Tumori J. 2008;94:718-723.
Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530:184-189.
Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, PA: Elsevier/Saunders; 2015.
Prigge ES, Toth C, Dyckhoff G, et al. p16(INK4a) /Ki-67 co-expression specifically identifies transformed cells in the head and neck region. Int J Cancer. 2015;136:1589-1599.
Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114:1299-1307.
Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479:232-236.
Romagosa C, Simonetti S, Lopez-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30:2087-2097.
Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest. 1999;79:1137-1143.
Moreira PR, Guimaraes MM, Gomes CC, et al. Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours. Arch Oral Biol. 2009;54:893-897.
Khojasteh A, Khodayari A, Rahimi F, et al. Hypermethylation of p16 tumor-suppressor gene in ameloblastic carcinoma, ameloblastoma, and dental follicles. J Oral Maxillofac Surg. 2013;71:62-65.
Artese L, Iezzi G, Piattelli A, et al. p16 expression in odontogenic cysts. Dent Res J. 2009;5:61-64.
Kumamoto H, Kimi K, Ooya K. Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med. 2001;30:309-315.
Kimi K, Kumamoto H, Ooya K, Motegi K. Immunohistochemical analysis of cell-cycle- and apoptosis-related factors in lining epithelium of odontogenic keratocysts. J Oral Pathol Med. 2001;30:434-442.
Olimid DA, Florescu AM, Cernea D, et al. The evaluation of p16 and Ki67 immunoexpression in ameloblastomas. Rom J Morphol Embryol. 2014;55:363-367.
Loyola AM, Cardoso SV, de Faria PR, et al. Adenoid ameloblastoma: clinicopathologic description of five cases and systematic review of the current knowledge. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:368-377.
Singh T, Angel C, Tabrizi S, Cornall A, Clement J. Ameloblastoma, human papillomavirus, and p16-is there an association. Arch Otolaryngol Rhinol. 2016;2:020-024.
Suzuki H, Sugimura H, Kitayama Y, et al. Expression of p16INK4A in ameloblastoma: immunohistochemical and FISH analysis. Oral Med Pathol. 2010;14:99-105.
Razavi SM, Poursadeghi H, Aminzadeh A. Immunohistochemical comparison of cyclin D1 and P16 in odontogenic keratocyst and unicystic ameloblastoma. Dent Res J (Isfahan). 2013;10:180-183.
Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36:131-149.
Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42-55.
El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012;34:459-461.
Duncan LD, Winkler M, Carlson ER, Heidel RE, Kang E, Webb D. p16 immunohistochemistry can be used to detect human papillomavirus in oral cavity squamous cell carcinoma. J Oral Maxillofac Surg. 2013;71:1367-1375.
Lewis JS Jr, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the college of american pathologists. Arch Pathol Lab Med. 2018;142:559-597.
Sedghizadeh PP, Billington WD, Paxton D, et al. Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis. Oral Oncol. 2016;54:15-27.
Satgunaseelan L, Virk SA, Lum T, Gao K, Clark JR, Gupta R. p16 expression independent of human papillomavirus is associated with lower stage and longer disease-free survival in oral cavity squamous cell carcinoma. Pathology. 2016;48:441-448.
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1992-1998.
Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005;11:3974-3986.
Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21:1424-1435.
Vijg J, Campisi J, Lithgow G. Mollecular and Cellular Biology of Aging. Washington, DC: The Gerentological Society of America; 2015.
Antonoglou GN, Sandor GK, Koidou VP, Papageorgiou SN. Non-syndromic and syndromic keratocystic odontogenic tumors: systematic review and meta-analysis of recurrences. J Craniomaxillofac Surg. 2014;42:e364-e371.
Rubini C, Mascitti M, Santarelli A, et al. Odontogenic tumors: a retrospective clinicopathological study from two Italian centers. Pathologica. 2017;109:35-46.
Laborde A, Nicot R, Wojcik T, Ferri J, Raoul G. Ameloblastoma of the jaws: management and recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134:7-11.
Moreira PR, Cardoso FP, Brito JA, Batista AC, Gomes CC, Gomez RS. Hypomethylation of tumor suppressor genes in odontogenic myxoma. Braz Dent J. 2011;22:422-427.
Moreira PR, Guimaraes MM, Guimaraes AL, et al. Methylation of P16, P21, P27, RB1 and P53 genes in odontogenic keratocysts. J Oral Pathol Med. 2009;38:99-103.
Nodit L, Barnes L, Childers E, Finkelstein S, Swalsky P, Hunt J. Allelic loss of tumor suppressor genes in ameloblastic tumors. Mod Pathol. 2004;17:1062-1067.
Loyola AM, Cardoso SV, de Faria PR, et al. Clear cell odontogenic carcinoma: report of 7 new cases and systematic review of the current knowledge. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:483-496.
Dos Santos JN, Servato JPS, Cardoso SV, de Faria PR, Pires BC, Loyola AM. Odontogenic carcinosarcoma: morphologic and immunohistochemical description of a case. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126:e264-e270.
Tan SH, Yeo JF, Pang BNK, Petersson F. An intraosseous sclerosing odontogenic tumor predominantly composed of epithelial cells: relation to (so-called) sclerosing odontogenic carcinoma and epithelial-rich central odontogenic fibroma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:e119-e125.
Mahajan A. Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol. 2016;51:64-74.
Kumamoto H, Ooya K. Immunohistochemical detection of retinoblastoma protein and E2 promoter-binding factor-1 in ameloblastomas. J Oral Pathol Med. 2006;35:183-189.